1. Introduction of a Polyethylene Glycol Linker Improves Uptake of 67 Cu-NOTA-Conjugated Lactam-Cyclized Alpha-Melanocyte-Stimulating Hormone Peptide in Melanoma.
- Author
-
Qiao, Zheng, Xu, Jingli, Fisher, Darrell R., Gonzalez, Rene, and Miao, Yubin
- Subjects
- *
MOLECULAR diagnosis , *MELANOMA , *NEUROPEPTIDES , *ANIMAL experimentation , *ANTINEOPLASTIC agents , *CELL receptors , *TREATMENT effectiveness , *DIAGNOSTIC imaging , *POLYETHYLENE glycol , *RESEARCH funding , *DESCRIPTIVE statistics , *SINGLE-photon emission computed tomography , *MOLECULAR structure , *AMIDES , *MICE , *PHARMACODYNAMICS - Abstract
Simple Summary: There is a need to develop new theranostic approaches for malignant melanoma. Only 35% of patients with metastatic melanoma reach the milestone of 5-year survival, despite the success of new immunotherapy. We have developed a new class of peptides to target melanocortin-1 receptors (MC1Rs) that display elevated levels in human melanoma. In this study, we examined the melanoma targeting and biodistribution properties of two 67Cu-tagged peptides in tumor-bearing mice. We found that one of the peptides, namely 67Cu-NOTA-PEG2Nle-CycMSHhex, exhibited favorable melanoma targeting and biodistribution properties that underscored its potential as an MC1R-targeted therapeutic peptide for melanoma treatment in the future. The aim of this study was to evaluate the effect of linker on tumor targeting and biodistribution of 67Cu-NOTA-PEG2Nle-CycMSHhex {67Cu-1,4,7-triazacyclononane-1,4,7-triyl-triacetic acid-polyethylene glycol-Nle-c[Asp-His-DPhe-Arg-Trp-Lys]-CONH2} and 67Cu-NOTA-GGNle-CycMSHhex {67Cu-NOTA-GlyGlyNle-CycMSHhex} on melanoma-bearing mice. NOTA-PEG2Nle-CycMSHhex and NOTA-GGNle-CycMSHhex were synthesized and purified by HPLC. The biodistribution of 67Cu-NOTA-PEG2Nle-CycMSHhex and 67Cu-NOTA-GGNle-CycMSHhex was determined in B16/F10 melanoma-bearing C57 mice. The melanoma imaging property of 67Cu-NOTA-PEG2Nle-CycMSHhex was further examined in B16/F10 melanoma-bearing C57 mice. 67Cu-NOTA-PEG2Nle-CycMSHhex exhibited higher tumor uptake than 67Cu-NOTA-GGNle-CycMSHhex at 2, 4, and 24 h post-injection. The tumor uptake of 67Cu-NOTA-PEG2Nle-CycMSHhex was 27.97 ± 1.98, 24.10 ± 1.83, and 9.13 ± 1.66% ID/g at 2, 4, and 24 h post-injection, respectively. Normal organ uptake of 67Cu-NOTA-PEG2Nle-CycMSHhex was lower than 2.6% ID/g at 4 h post-injection, except for kidney uptake. The renal uptake of 67Cu-NOTA-PEG2Nle-CycMSHhex was 6.43 ± 1.31, 2.60 ± 0.79, and 0.90 ± 0.18% ID/g at 2, 4, and 24 h post-injection, respectively. 67Cu-NOTA-PEG2Nle-CycMSHhex showed high tumor to normal organ uptake ratios after 2 h post-injection. The B16/F10 melanoma lesions could be clearly visualized by single photon emission computed tomography (SPECT) using 67Cu-NOTA-PEG2Nle-CycMSHhex as an imaging probe at 4 h post-injection. The favorable tumor targeting and biodistribution properties of 67Cu-NOTA-PEG2Nle-CycMSHhex underscored its potential as an MC1R-targeted therapeutic peptide for melanoma treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF